股票代码：300363 股票简称：博腾股份 公告编号：2023-060号 重庆博腾制药科技股份有限公司 关于增聘高级管理人员的公告 截至本公告披露日，马雄斌先生未直接及间接持有公司任何股份，未在其他 单位或者公司兼职，与持有公司 5%以上股份的股东、实际控制人及公司其他董 事、监事、高级管理人员不存在关联关系，未受过中国证监会及其他有关部门的 处罚和证券交易所惩戒，不存在《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》第 3.2.3 条所规定的情形，也不属于失信被执行 人，符合《公司法》等相关法律、法规和规定要求的任职条件。 黄渊明，男，中国国籍，出生于 1979 年 8 月，硕士。曾就职于华为技术有 限公司、顺丰控股有限公司、天音通信控股股份有限公司、盈佳信联科技集团有 限公司、上海云砺信息科技有限公司等企业，拥有 20 年人力资源管理经验。现 任公司副总经理，负责公司人力资源管理工作。 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日 召开第五届董事会第十八次会议，审议通过《关于增聘高级管理人员的议案》， 结合公司经营发展需要，同意增聘马雄斌先生、 ...

Financial Performance - The company's revenue for Q1 2023 was ¥1,377,802,786.78, a decrease of 4.50% compared to ¥1,442,770,395.49 in the same period last year[3] - Net profit attributable to shareholders was ¥304,092,146.15, down 20.37% from ¥381,898,709.67 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥296,262,380.67, reflecting a decline of 22.24% compared to ¥381,009,392.25 in the previous year[3] - Basic and diluted earnings per share were both ¥0.56, down 20.00% from ¥0.70 in the previous year[3] - In Q1 2023, the company achieved total revenue of 1.378 billion yuan, a year-on-year decrease of approximately 5% due to the delivery of significant orders received in previous periods[16] - The net profit attributable to shareholders was 358 million yuan, down about 14% year-on-year, primarily due to losses from emerging businesses[16] Cash Flow and Operating Activities - The company's cash flow from operating activities increased by 8.68% to ¥363,297,371.75 from ¥334,267,821.88 in the same period last year[3] - In Q1 2023, the company received cash related to operating activities amounting to ¥167,052,654.12, a significant increase of 539.25% compared to ¥26,132,511.55 in Q1 2022, primarily due to an increase in the recovery of deposit guarantees[9] - The cash paid for purchasing goods and services was ¥803,815,554.48, reflecting a 49.24% increase from ¥538,622,704.50 in the same period last year, attributed to higher procurement payments[9] - Cash paid for other operating activities decreased by 40.26% to ¥77,319,398.81 from ¥129,436,828.59, mainly due to a reduction in deposit guarantees paid[9] - Total cash inflow from operating activities reached CNY 1,698,129,800.41, compared to CNY 1,395,007,604.29 in the same period last year, indicating a year-over-year increase of about 21.7%[30] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥10,023,735,617.15, a decrease of 1.19% from ¥10,144,292,774.55 at the end of the previous year[3] - Total liabilities decreased to CNY 3,240,995,132.55 from CNY 3,672,000,486.45, a reduction of 11.7%[25] - Non-current liabilities increased to CNY 911,552,118.09 from CNY 656,007,317.81, an increase of 38.8%[25] - The company's total equity rose to CNY 6,782,740,484.60, up from CNY 6,472,292,288.10, indicating a growth of 4.8%[25] Research and Development - Research and development expenses rose by 58.20% to ¥165,970,275.02, driven by an increase in R&D personnel and ongoing investments in technology platforms[8] - Research and development expenses increased to CNY 165,970,275.02, up 58% from CNY 104,914,096.80 in Q1 2022[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 62,971[11] - The largest shareholder, Chongqing Liangjiang New Area Industrial Development Group Co., Ltd., holds 14.46% of the shares, totaling 78,982,719 shares[11] Strategic Investments - The company’s strategic investments included the acquisition of 100% equity in Kaihui Pharmaceutical (Shanghai) Co., Ltd[16] Employee and Operational Metrics - The company’s employee count rose to 5,377, a 29% increase compared to the same period last year[16] - The company reported a total of 299 signed customer orders, representing a year-on-year growth of approximately 30%[16] - The number of single customers increased to 37, marking a year-on-year growth of 68%[16] Tax and Government Subsidies - The company received government subsidies amounting to ¥10,058,624.94, an increase of 263.12% compared to ¥2,770,023.02 in the previous year[8] - The company reported a significant increase in tax expenses, with a decrease in profit leading to a tax expense of ¥38,052,887.60, down 36.02% from ¥59,477,591.43 in the previous year[8] - The company received CNY 79,897,199.77 in tax refunds, compared to CNY 98,430,190.82 in the previous year, reflecting a decrease of approximately 18.5%[30] Cash and Financing Activities - Cash received from borrowings was ¥159,806,540.09, a decrease of 71.42% compared to ¥559,126,133.95, primarily due to reduced bank borrowings[9] - Cash paid for debt repayment was ¥127,298,000.00, down 59.50% from ¥314,350,305.64, reflecting a decrease in bank loan repayments[9] - The company distributed dividends and interest payments totaling ¥5,086,369.72, a decrease of 67.49% from ¥15,644,093.33, attributed to lower interest payments[9] - The net cash flow from financing activities was CNY 32,743,083.39, down from CNY 255,142,167.21 in Q1 2022, indicating a decrease of approximately 87.2%[30] Audit Information - The company did not conduct an audit for the Q1 2023 report[31]

Group 1: Strategic Focus Areas - The company's strategic focus for 2023 revolves around five key areas: "end-to-end" capabilities, globalization, new business development, digitalization, and breakthroughs in new technologies [1][2]. - The emphasis on "end-to-end" capabilities aims to enhance early-stage services in the CDMO sector [1]. - Globalization is viewed as both a challenge and an opportunity, prompting organizational and business transformations [2]. Group 2: Financial Performance and Projections - In 2022, the company experienced significant increases in gross margin and net profit margin due to high capacity utilization and cost-reduction R&D efforts [2][3]. - For 2023, a decline in gross and net profit margins is anticipated due to the completion of large orders and ongoing investments in new business ventures [2][3]. Group 3: Expense Management - The increase in expenses in 2022 was attributed to higher management, sales, and R&D costs, driven by organizational expansion and ongoing technology development [3]. - The company expects overall expenses in 2023 to remain stable compared to 2022, although the expense ratio may rise [3]. Group 4: Shareholder Returns - The company announced a cash dividend payout ratio of 30% for 2022, totaling CNY 602 million, alongside a share buyback amounting to CNY 1 billion, reflecting a commitment to shareholder returns [5]. Group 5: Risk Management and Challenges - The company faces macroeconomic challenges, including geopolitical influences, a difficult financing environment, and the need for technological advancements [6]. - Emphasis is placed on enhancing internal controls and compliance to mitigate risks associated with international operations [4][6].

关于举行 2022 年度网上业绩说明会的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 25 日在巨潮资讯网（www.cninfo.com.cn）披露 2022 年年度报告及其摘要。为让广 大投资者更加深入、全面地了解公司 2022 年度经营情况，公司定于 2023 年 4 月 14 日（星期五）15:00-16:30 举办 2022 年度业绩说明会，与投资者进行互动交流。 一、业绩说明会召开的时间、地点、方式 1、会议召开时间：2023 年 4 月 14 日（星期五）15:00-16:30 股票代码：300363 股票简称：博腾股份 公告编号：2023-031 号 重庆博腾制药科技股份有限公司 欢迎广大投资者积极参与本次业绩说明会！ (问题征集专题页面二维码) 2、会议召开地点：全景网"投资者关系互动平台" 3、会议召开方式：视频及网络互动 二、出席人员 出席本次说明会的人员有：公司董事长、总经理居年丰先生，副总经理、财 务负责人陈晖先生，副总经理、董事会秘书皮薇女士，独立董事袁 ...

Group 1: Market Trends and Production Capacity - Overseas CDMO companies are experiencing price increases due to inflation, but strategies vary by business segment and market [1] - The capacity utilization rates of the three factories differ slightly, with the Jiangxi factory maintaining a high utilization rate, while the Changshou and Hubei factories are gradually filling their capacities [1] - The company’s formulation factory projects are currently all from domestic clients [2] Group 2: Project Developments and Future Plans - The Slovenia project, announced in 2022, is in the early engineering design phase and is expected to be operational by Q3 2024, serving as a research and production base in Europe [2] - The company is involved in the entire ADC service cycle due to its capabilities in small molecules [2] - The GCT business pipeline is primarily in the preclinical stage, with two client projects successfully applying for IND last year [3] Group 3: Business Strategy and Talent Expansion - The company’s new business layout is driven by both market demand and proactive planning [2] - In 2022, the company expanded its workforce by approximately 1,700 employees, with 2023 recruitment focusing on new business and capabilities [3] - The company plans to consider specific financing plans based on business needs [3] Group 4: Financial and Capital Expenditure - The company’s capital expenditure plan for 2022 was approximately 1.7 billion, with actual execution within this range [3] - The number of commercialized API projects remains in single digits, but the number of PV projects has reached several dozen over the past two years, with more commercial projects expected to materialize after 2024 [3]

Group 1: Business Operations - The company's intermediates business involves few pre-clinical products, primarily focusing on commercialized intermediates [1] - New drug application processes are mainly based on client-provided technology packages, which require multiple technical improvements for mass production [1] - The company is planning to implement stock incentives, but cannot review such matters within six months after terminating previous incentives [1] Group 2: Market and Revenue Insights - The revenue distribution for the first three quarters of the year is primarily from three major therapeutic areas: anti-HIV, anti-hepatitis C, and anti-diabetes [2] - The main contributor to anti-diabetes products in the first half of the year is Johnson & Johnson [2] - The company maintains its initial sales budget for the fourth quarter based on current order conditions [2] Group 3: Environmental and Compliance Risks - The company acknowledges environmental risks associated with its chemical production but has established a robust EHS management system to address these concerns [2] - Client audits are project-based and ongoing, rather than a one-time event [2] Group 4: Capacity and Expansion Plans - Currently, there are no plans for new workshops as existing capacity meets order demands [2] - The company does not have performance commitments from the acquired Jiangxi Dongbang Pharmaceutical Co., Ltd., as it is the largest customer of Dongbang [2]